Trial Profile

Administration of an Allogeneic Myeloma GM-CSF Vaccine in Conjunction With a Lenalidomide Containing Regimen in Myeloma Patients With Near Complete Remission

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenalidomide (Primary) ; Multiple myeloma vaccine (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
Indications Multiple myeloma
Focus Proof of concept; Therapeutic Use

Most Recent Events

19 Oct 2021 Results published in the Clinical Cancer Research
08 Dec 2020 Primary endpoint (Response Conversion Rate description) has been met, according to results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com